Daiichi Sankyo Company, Limited (DSKYF)
| Previous close | 33.39 |
| Open | 33.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 33.09 - 33.25 |
| 52-week range | 19.45 - 34.39 |
| Volume | |
| Avg. volume | 2,332 |
| Market cap | 63.999B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 132.36 |
| EPS (TTM) | 0.25 |
| Earnings date | N/A |
| Forward dividend & yield | 0.24 (0.71%) |
| Ex-dividend date | 30 Mar 2023 |
| 1y target est | 37.91 |
- Business Wire
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J., January 30, 2023--Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy, in patients with previously untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with PD-L1 expression less than 50% (TPS<50%) and without actionable genomic alterations.
- Business Wire
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
TOKYO & MUNICH, January 26, 2023--ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
- Business Wire
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
TOKYO & MUNICH, January 04, 2023--ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
